J. Fernando Arevalo, MD, summarizes his discussion on time from intravitreal bevacizumab (Avastin, Genentech) injection to vitrectomy in cases of severe proliferative diabetic retinopathy (PDR). He provides important data from his group’s collaboration with other groups.
6 / 12 Series: 2017 Retina World Congress Meeting
post as anonymous